Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26984937 | 0.79 | GRM5 (0.31) | GRM5 | |
| SCHEMBL15359012 | 0.79 | HTT (0.58) | NOS3NOS1NOS2HTT | |
| SCHEMBL23537645 | 0.79 | — | — | |
| SCHEMBL20915728 | 0.78 | MTOR (0.36) | — | |
| SCHEMBL20929147 | 0.77 | LOX (0.32) | — | |
| SCHEMBL28449756 | 0.76 | EGLN2 (0.38) | GRM5 | |
| SCHEMBL1644262 | 0.75 | GRM5 (0.48) | GRM5 | |
| SCHEMBL20915736 | 0.73 | HTT (0.37) | NOS3NOS1NOS2HTTMET | |
| SCHEMBL30692233 | 0.73 | HTT (0.60) | GRM5HTTMET | |
| SCHEMBL15688896 | 0.73 | HTT (0.60) | GRM5HTTMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2021-08-05 | — | — | US | disclosed |
| US-11020397-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200268757-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200197393-A9 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC | 2020-06-25 | — | — | US | disclosed |
| US-10688095-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190117654-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688095-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, UGT2B7 | NOS3 1467/4885NOS1 1748/4885NOS2 1929/4885 |
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | NOS3 849/4885NOS1 813/4885NOS2 793/4885 |
| US-20200268757-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | NOS3 849/4885NOS1 813/4885NOS2 793/4885 |
| US-11020397-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, UGT2B7 | NOS3 1467/4885NOS1 1748/4885NOS2 1929/4885 |
| US-20200197393-A9 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | NOS3 849/4885NOS1 813/4885NOS2 793/4885 |
| US-20190117654-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | NOS3 849/4885NOS1 813/4885NOS2 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.